The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

Since the first introduction of sodium iodide I-131 for use with thyroid patients almost 80
years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range …

Fibroblast activation protein (FAP) has become an attractive target for diagnosis and
therapy, and a series of FAP inhibitor (FAPI)–based radiotracers has been developed and …

Introduction Radiopharmaceuticals that target cancer-associated fibroblasts (CAFs) have
become an increasingly attractive strategy for cancer theranostics. Recently, a series of …

Prostate cancer is a leading cause of cancer death in men worldwide. Among the various
treatment options, radiopharmaceutical therapy has shown notable success in metastatic …

Abstract Rationale: Small 225 Ac-labeled prostate-specific membrane antigen (PSMA)-
targeted radioconjugates have been described for targeted alpha therapy of metastatic …

Tumor heterogeneity limits the efficacy and reliability of monospecific radiopharmaceuticals
in prostate cancer diagnosis and therapy. To overcome this limitation and improve lesion …

Simple Summary One of the most frequently diagnosed cancer in men is adenocarcinoma of
the prostate. Once the disease is metastatic, only very limited treatment options are …

Prostate-specific membrane antigen (PSMA) is a promising target for metastatic castration-
resistant prostate cancer. We previously reported the effectiveness of PSMA-DA1 as a PSMA …

The aim of this study was to investigate the effect of replacing Glu in the Lys-urea-Glu PSMA-
targeting pharmacophore of [68 Ga] Ga-HTK03041 with a close analog on the uptake of …